Advances in Liposomes-Based-Therapeutics as Cutting-Edge for Ocular Fungal Infections: An Updated Review

The drug delivery through the eye has been challenging due to the complex physiology of the eye. The ocular region is commonly considered the most advantageous site for the topical application of medicines for management of eye disorders. The effectiveness of this approach is commonly impeded by the strong protective mechanisms of eye, leading to restricted access of the drugs. Ocular fungal infections are commonly reported as one of the predominant eye illnesses caused by various fungal species like Fusarium species, Candida glabrata, Aspergillus flavus, and Aspergillus fumigatus. Liposomes are biocompatible lipid nanocarriers which have emerged as innovative therapeutic technologies in ophthalmology to overcome ocular obstacles, provide targeted drug delivery along with enhancement of drug’s safety margin. This review elucidates about causes of ocular fungal infection, fungal evasion by host immune system, pharmacological profile of drug used for treatment of ocular fungal infections, and challenges of existing formulations in management of ocular infections. This article focused upon the current advancements in domain of topical applications of liposomes of ophthalmic medicines in management of ocular fungal infection.